Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
NRAS and/or KRAS2 mutations were found in 54.5% of MM at diagnosis (but in 81% at the time of relapse), in 50% of P-PCL, and in 50% of 16 HMCL.
|
11524732 |
2001 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.
|
11520807 |
2001 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings identify a significant clinical impact of NRAS mutation in myeloma and demonstrate a clear example of functional differences between the KRAS and NRAS oncogenes.
|
24335104 |
2014 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Point mutations within the P53 and N-RAS genes were presumably related to the rapidly progressive disease in this particular MM patient.
|
11672773 |
2001 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Akt pathway counts among the signaling conduits for oncogenic RAS and activating mutations of K- and N-RAS frequently occur in MM.
|
21149634 |
2011 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Flow cytometric analysis using annexin V and 7-aminoactinomycin D (7AAD) showed that R115777 induced apoptosis of 2 of 3 myeloma cell lines at a concentration of 1.0 x 10(-8) M. R115777 appears to be a potent inducer of apoptosis, and its effects depend on the status of Ras mutation in cloned myeloma cells but not on the status of N-Ras mutation in fresh myeloma cells.
|
12842991 |
2003 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To assess a possible role in tumor progression, the occurrence and type of K- and N-RAS mutations were determined in purified tumor cells, including samples from patients with premalignant monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), and extramedullary plasma cell (PC) tumors (ExPCTs).
|
15339850 |
2005 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that the PT-LPDs are divisible into three distinct categories as follows: (1) plasmacytic hyperplasia: most commonly arise in the oropharynx or lymph nodes, are nearly always polyclonal, usually contain multiple EBV infection events or only a minor cell population infected by a single form of EBV, and lack oncogene and tumor suppressor gene alterations; (2) polymorphic B-cell hyperplasia and polymorphic B-cell lymphoma: may arise in lymph nodes or various extranodal sites, are nearly always monoclonal, usually contain a single form of EBV, and lack oncogene and tumor suppressor gene alterations; and (3) immunoblastic lymphoma or multiple myeloma: present with widely disseminated disease, are monoclonal, contain a single form of EBV, and contain alterations of one or more oncogene or tumor suppressor genes (N-ras gene codon 61 point mutation, p53 gene mutation, or c-myc gene rearrangement).
|
7812011 |
1995 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The spectrum of KRAS, NRAS, and BRAF codon mutations varied across subgroups with NRAS mutations at Q61 codon being common in hyperdiploid (HRD) and t(11;14) myeloma while being rare in MMSET and MAF.
|
28427158 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KRAS and NRAS exon 3 mutations were significantly associated with the myeloma cohort compared with non-myeloma plasma cell dyscrasias (odds ratio (OR) 9.87, 95% confidence interval (CI) 1.07-90.72, P=0.043 and OR 7.03, 95% CI 1.49-33.26, P=0.014).
|
28234344 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Forty-eight newly diagnosed myeloma patients were tested with the panel, which included IGH and six genes that are recurrently mutated in myeloma: NRAS, KRAS, HRAS, TP53, MYC, and BRAF.
|
27863261 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma.
|
16321859 |
2006 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
None of the driver gene mutations frequently found in multiple myeloma (MM) such as NRAS, KRAS, BRAF, and TP53 was detected.
|
30635632 |
2019 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
As the mutation was observed only at the N-RAS oncogene level, it is speculated that N-RAS oncogene activation might play an important role in the progression of multiple myeloma.
|
1421173 |
1992 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ANBL-6, a myeloma cell line, proliferates in response to interleukin 6 (IL-6) stimulation, coculture with bone marrow stromal cells, and when harboring a constitutively active mutant N-ras gene.
|
12791645 |
2003 |
Multiple Myeloma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|